ISSN Druckformat: 2151-805X
ISSN Online: 2151-8068
Transplantation for Older Patients with Hematologic Malignancies in 2021: Uncertainty and Ethics in Decision-Making
Get access
ABSTRAKT
Hematological malignancies such as acute myeloid leukemia or myelodysplastic syndrome occur predominantly in older individuals. For many of these patients, hematopoietic cell transplantation is currently the only treatment modality with curative potential. However, older age tends to be associated with increasing co-morbidities, rendering patients more susceptible to toxicities associated with the transplantation procedure. Further, transplantation carries the risk of inducing graft-versus-host disease, the clinical result of the immunological attack of donor cells against the patient's body, even if the donor is matched (for human leukocyte antigen) with the patient. These complications affect quality of life and may prove fatal. More conventional chemotherapy does not carry the risk of these complications; however, in most patients, it does not cure the disease. Therefore, multiple patient and disease characteristics are being considered in the decision-making process regarding the two treatment strategies, and the decision is generally based on statistics from previous studies. Of course, those statistics do not consider individual patient personalities nor physician attitudes, which clearly affect patient decisions. Thus, these discussions involve considerable uncertainty and ethical considerations as to the greatest benefit at the lowest "cost" for the patient.
-
Rosko AE, Cordoba R, Abel G, Artz A, Loh KP, Klepin HD. Advances in management for older adults with hematologic malignancies. J Clin Oncol. 2021;39(19):2102-14.
-
Deeg HJ. Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients. Bone Marrow Transplant. 2015;50(9):1145-9.
-
Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, Bhatia S, Ostronoff F, Deeg HJ, Syrjala KL, Estey E, Maloney DG, Appelbaum FR, Martin PJ, Storer BE. Comorbidity-age index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32(29):3249-56.
-
Deeg HJ, Steuten LM. Therapy for hematologic cancers in older patients, quality of life, and health economics: Difficult decisions. JAMA Oncol. 2015;1(5):571-2.
-
Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-5.
-
Bories P, Lamy S, Simand C, Bertoli S, Delpierre C, Malak S, Fornecker L, Moreau S, Recher C, Nebout A. Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: Results of a national survey. Haematologica. 2018;103(12):2040-8.
-
Kahneman D, Tversky A. Prospect theory: An analysis of decision under risk. Econometrica. 1979;47(2):263-91.
-
Dhawale T, Steuten LM, Deeg HJ. Uncertainty of physicians and patients in medical decision making. Biol Blood Marrow Transplant. 2017;23(6):865-9.
-
Short NJ, Tallman MS, Pollyea DA, Ravandi F, Kantarjian H. Optimizing risk stratification in acute myeloid leukemia: Dynamic models for a dynamic therapeutic landscape. J Clin Oncol. 2021;39(23):2535-8.